Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016
Published Jun 08, 2016
75 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016, provides an overview of the Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
- The report reviews pipeline therapeutics for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) therapeutics and enlists all their major and minor projects
- The report assesses Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
- Identify potential

  
Source:
Document ID
GMDHC8188IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Overview91
Therapeutics Development102
  Pipeline Products for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Overview101
  Pipeline Products for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Comparative Analysis111
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics under Development by Companies121
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics under Investigation by Universities/Institutes131
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Pipeline Products Glance142
  Clinical Stage Products141
  Early Stage Products151
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Products under Development by Companies161
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Products under Investigation by Universities/Institutes171
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Companies Involved in Therapeutics Development1811
  Abeona Therapeutics, Inc.181
  Alexion Pharmaceuticals, Inc.191
  ArmaGen Inc.201
  Axcentua Pharmaceuticals AB211
  BioMarin Pharmaceutical Inc.221
  Dorphan S.A.231
  Laboratorios Del Dr. Esteve S.A.241
  Lysogene251
  Shire Plc261
  Swedish Orphan Biovitrum AB271
  UniQure N.V.281
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3823
  ABO-101 - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  ABO-102 - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  AGT-184 - Drug Profile401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  AMT-110 - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress412
  AXP-10711 - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress432
  BMN-250 - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  EGT-101 - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  EGT-201 - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress471
  LYSSAF-301 - Drug Profile481
    Product Description481
    Mechanism of Action481
    R&D Progress482
  LYSSAF-302 - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  Proteins for Sanfilippo Syndrome - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress511
  Recombinant N-Acetylgalactosamine-6-Sulfatase Replacement for Mucopolysaccharidosis Type IIID - Drug Profile521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  SBC-103 - Drug Profile531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  SHP-610 - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  Small Molecule for Sanfilippo Syndrome - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  Small Molecule to Target Alpha-N-Acetylglucosaminidase for MPSIIIB - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  SOBI-003 - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress571
  Stem Cell Therapy for Mucopolysaccharidosis Type IIIA - Drug Profile581
    Product Description581
    Mechanism of Action581
    R&D Progress581
  Stem Cell Therapy for Sanfilippo Syndrome - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  Stem Cell Therapy to Activate NAG for Mucopolysaccharidosis III - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Recent Pipeline Updates617
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Dormant Projects681
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Product Development Milestones695
  Featured News &Press Releases691
    May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)691
    Feb 25, 2016: ESTEVE Provides Update On EGT-101 For Sanfilippo A Syndrome701
    Feb 25, 2016: ESTEVE Provides Update On EGT-201 For Sanfilippo B Syndrome701
    Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome711
    May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-101 From FDA721
    Apr 02, 2014: Orphan designation granted for MPSIII721
    Jul 25, 2013: New stem cell gene therapy gives hope to prevent inherited neurological disease721
    Apr 11, 2013: Axcentua granted patent on ten solid forms of genistein731
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-III-MPS-III-Sanfilippo-Syndrome-Pipeline-Review-H1-2016-2088-15920>
  
APA:
Global Markets Direct - Market Research. (2016). Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-III-MPS-III-Sanfilippo-Syndrome-Pipeline-Review-H1-2016-2088-15920>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.